Molecular Biology Reports

, Volume 37, Issue 7, pp 3227–3232

TGFBR1*6A/9A polymorphism and cancer risk: a meta-analysis of 13,662 cases and 14,147 controls

  • Ru-Yan Liao
  • Chen Mao
  • Li-Xin Qiu
  • Hong Ding
  • Qing Chen
  • Hai-Feng Pan
Article

DOI: 10.1007/s11033-009-9906-7

Cite this article as:
Liao, RY., Mao, C., Qiu, LX. et al. Mol Biol Rep (2010) 37: 3227. doi:10.1007/s11033-009-9906-7

Abstract

Published data on the association between TGFBR1*6A/9A polymorphism and cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. A total of 32 studies including 13,662 cases and 14,147 controls were involved in this meta-analysis. Overall, significantly elevated cancer risks were associated with TGFBR1*6A in all genetic models (for allelic effect: OR = 1.11; 95% CI = 1.03–1.21; for 6A/6A vs. 9A/9A: OR = 1.30; 95% CI = 1.01–1.69; for 9A/6A vs. 9A/9A: OR = 1.08; 95% CI = 1.01–1.15; for dominant model: OR = 1.08; 95% CI = 1.02–1.15; for recessive model: OR = 1.29; 95% CI = 1.00–1.68). In the subgroup analysis by cancer types, significant associations were found in breast cancer (for allelic effect: OR = 1.16; 95% CI = 1.01–1.34) and ovarian cancer (for allelic effect: OR = 1.24; 95% CI = 1.00–1.54; for 6A/6A vs. 9A/9A: OR = 2.34; 95% CI = 1.03–5.33). However, no significant associations were found in colorectal cancer, bladder cancer, prostate cancer and lung cancer for all genetic models. In summary, this meta-analysis suggests that the TGFBR1*6A/9A polymorphism is associated with cancer susceptibility, increasing the risk of breast and ovarian cancer.

Keywords

TGFBR1 Polymorphism Cancer Susceptibility Meta-analysis 

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Ru-Yan Liao
    • 1
  • Chen Mao
    • 1
  • Li-Xin Qiu
    • 2
  • Hong Ding
    • 3
  • Qing Chen
    • 1
  • Hai-Feng Pan
    • 4
  1. 1.Department of Epidemiology, School of Public Health and Tropical MedicineSouthern Medical UniversityGuangzhouChina
  2. 2.Cancer Center, Nanjing Drum Tower HospitalNanjing Medical UniversityNanjingChina
  3. 3.Longgang Center for Disease Control and Prevention of ShenzhenShenzhenChina
  4. 4.Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical UniversityHefeiChina

Personalised recommendations